Abstract
Tumorigenesis is a complex and multistep process involving genetic and epigenetic changes within the tumor cell, as well as supportive conditions within the tumor microenvironment (TME). The TME is widely implicated in tumorigenesis because it harbors tumor cells that interact with surrounding cells through the circulatory and lymphatic systems to influence the development and progression of cancer. Moreover, nonmalignant cells in the TME play essential roles in all stages of carcinogenesis by stimulating and facilitating uncontrolled cell proliferation. A key contributory condition is angiogenesis, blood vessel growth, which plays a critical role in the growth of cancer as solid tumors require a blood supply to grow past a few millimeters in size. Tumors promote this blood supply to form by releasing chemical signals that stimulate angiogenesis. Angiogenesis is a major point of biomedical research that has led to the clinical approval of several antiangiogenic agents resulting in new treatment strategies. This chapter outlines some of the most important aspects of the interrelationship between tumor cells and its microenvironment leading to tumor progression. The focus is on angiogenesis and incorporates novel antiangiogenic strategies and therapies.
Similar content being viewed by others
References
Albini A et al (2018) Contribution to tumor angiogenesis from innate immune cells within the tumor microenvironment: implications for immunotherapy. Front Immunol 5(9):527
Biswas SK, Allavena P, Mantovani A (2013) Tumor-associated macrophages: functional diversity, clinical significance, and open questions. Semin Immunopathol 35(5):585–600
Borsi E et al (2015) Therapeutic targeting of hypoxia and hypoxia-inducible factor 1 alpha in multiple myeloma. Transl Res 165(6):641–650
Brencicova E, Jagger AL, Evans HG, Georgouli M, Laios A, Attard Montalto S et al (2017) Interleukin-10 and prostaglandin E2 have complementary but distinct suppressive effects on toll-like receptor-mediated dendritic cell activation in ovarian carcinoma. PLoS One 12(4):e0175712
Bruix J et al (2017) Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies. Journal of Hepatology 67(5):999–1008
Cadet J, Wagner JR (2013) DNA base damage by reactive oxygen species, oxidizing agents, and UV radiation. Cold Spring Harb Perspect Biol 5(2):a012559
Carmeliet P, Jain RK (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature 473:298–307
Carrega P, Campana S, Bonaccorsi I, Ferlazzo G (2016) The Yin and Yang of innate lymphoid cells in cancer. Immunol Lett 179:29–35
Chakraborty S et al (2020) Agrin mediates angiogenesis in the tumor microenvironment. Trends Cancer 6(2):81–85
Chen CY, Wu SM, Lin YH, Chi HC, Lin SL, Yeh CT et al (2019) Induction of nuclear protein-1 by thyroid hormone enhances platelet-derived growth factor A mediated angiogenesis in liver cancer. Theranostics 9(8):2361–2379
Del Zotto G, Marcenaro E, Vacca P, Sivori S, Pende D, Della Chiesa M et al (2017) Markers and function of human NK cells in normal and pathological conditions. Cytometry B Clin Cytom 92(2):100–114
Ferrara N, Hillan KJ, Gerber HP, Novotny W (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3(5):391–400
Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285(21):1182–1186
Frentzas S, Lum C, Ting-Yu C (2020) Angiogenesis and its role in the tumour microenvironment: a target for cancer therapy. In: Rajer M, Segelov E (eds) Current cancer treatment. IntechOpen, London
Gentles AJ et al (2015) The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med 21:938–945
Gillgrass AE et al (2015) Recent advances in the use of NK cells against cancer. In: Rezaei N (ed) Cancer immunology: bench to bedside immunotherapy of cancers. Springer, Cham
Gordon-Weeks A et al (2017) Neutrophils promote hepatic metastasis growth through fibroblast growth factor 2–dependent angiogenesis in mice. Hepatology 65(6):1920–1935
Guerrero PA, McCarthy JH (2016) TGF-b activation and signaling in angiogenesis. In: Simionescu D, Simionescu A (eds) Physiologic and pathologic angiogenesis – signaling mechanisms and targeted therapy. IntechOpen, London
Guo C, Buranych A, Sarkar D, Fisher PB, Wang XY (2013) The role of tumor associated macrophages in tumor vascularization. Vasc Cell 5(1):20
Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86(3):353–364
Jiang X et al (2020) The role of microenvironment in tumor angiogenesis. J Exp Clin Cancer Res 39:Article number: 204
Jorgovanovic D et al (2020) Roles of IFN-g in tumor progression and regression: a review. Biomark Res 8:49
Kuczynski EA et al (2019) Vessel co-option in cancer. Nat Rev Clin Oncol 16(8):469–493
Lapeyre-Prost A, Terme M et al (2017) Immunomodulatory activity of VEGF in cancer. Int Rev Cell Mol Biol 330:295–342
Lewis C, Murdoch C (2005) Macrophage responses to hypoxia. Am J Pathol 167(3):627–635
Liang S, Yu H, Chen X, Shen T, Cui Z, Si G et al (2017) PDGF-BB/KLF4/VEGF signaling axis in pulmonary artery endothelial cell angiogenesis. Cell Physiol Biochem 41(6):2333–2349
Lopes-Coelho F et al (2021) Anti-angiogenic therapy: current challenges and future perspectives. Int J Mol Sci 22(7):3765
Lugano R et al (2020) Tumor angiogenesis: causes, consequences, challenges and opportunities. Cell Mol Life Sci 77(9):1745–1770
Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P (2017) Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol 14(7):399–416
Martin P, Leibovich SJ (2005) Inflammatory cells during wound repair: the good, the bad and the ugly. Trends Cell Biol 15(11):599–607
Mattner J, Wirtz S (2017) Friend or foe? The ambiguous role of innate lymphoid cells in cancer development. Trends Immunol 38(1):29–38
Mjosberg J, Spits H (2016) Human innate lymphoid cells. J Allergy Clin Immunol 138(5):1265–1276
Motz GT, Coukos G (2011) The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat Rev Immunol 11(10):702–711
Mukhtar RA, Nseyo O, Campbell MJ, Esserman LJ (2011) Tumor-associated macrophages in breast cancer as potential biomarkers for new treatments and diagnostics. Expert Rev Mol Diagn 11(1):91–100
Murdoch C, Giannoudis A, Lewis C (2004) Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 104(8):224–234
Murphy JF (2014) Modulation of angiogenesis by tumor associated macrophages in the tumor microenvironment. MOJ Immunol 1(3):00016
Murphy JF (2017) Anti-cancer therapy: non-steroidal anti-inflammatory drugs (NSAIDS) in combination with immunotherapy. MOJ Immunol 5(3):00156
Murphy J et al (2005) Engagement of CD44 modulates cyclooxygenase induction, VEGF generation, and proliferation in human vascular endothelial cells. FASEB J 446–8
Nishikawa H, Sakaguchi S (2010) Regulatory T cells in tumor immunity. Int J Cancer 127:759–767
Noy R, Pollard JW (2014) Tumor-associated macrophages: from mechanisms to therapy. Immunity 41(1):49–61
Ohm JE, Gabrilovich DI et al (2003) VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood 101:4878–4886
Oklu R et al (2017) Neutrophil extracellular traps are increased in cancer patients but does not associate with venous thrombosis. Cardiovasc Diagn Ther 7:S140–S149
Park J, Lee SE, Hur J, Hong EB, Choi JI, Yang JM et al (2015) M-CSF from cancer cells induces fatty acid synthase and PPARbeta/delta activation in tumor myeloid cells, leading to tumor progression. Cell Rep 10(9):1614–1625
Qian BZ, Pollard JW (2010) Macrophage diversity enhances tumor progression and metastasis. Cell 141(1):39–51
Queen MM, Ryan RE, Holzer RG, Keller-Peck CR, Jorcyk CL (2005) Breast cancer cells stimulate neutrophils to produce oncostatin M: potential implications for tumor progression. Cancer Res 65:8896–8904
Rohlenova K, Veys K et al (2018) Endothelial cell metabolism in health and disease. Trends Cell Biol 28:224–236
Rusnati M, Presta M (2007) Fibroblast growth factors/fibroblast growth factor receptors as targets for the development of anti-angiogenesis strategies. Curr Pharm Des 13(20):2025–2044
Sangaletti S et al (2014) Defective stromal remodeling and neutrophil extracellular traps in lymphoid tissues favor the transition from autoimmunity to lymphoma. Cancer Discov 4:110–129
Semenza GL (2009) Regulation of cancer cell metabolism by hypoxia-inducible factor 1. Semin Cancer Biol 19(1):12–16
Shibuya M (2006) Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol 39(5):469–478
Sica A, Bronte V (2007) Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 117(5):1155–1166
Spits H, Artis D, Colonna M, Diefenbach A, Di Santo JP, Eberl G et al (2013) Innate lymphoid cells – a proposal for uniform nomenclature. Nat Rev Immunol 13(2):145–149
Tanaka K, Watanabe M, Tanigaki S, Iwashita M, Kobayashi Y (2018) Tumor necrosis factor-alpha regulates angiogenesis of BeWo cells via synergy of PlGF/VEGFR1 and VEGF-A/VEGFR2 axes. Placenta 74:20–27
Toomey D et al (2010) Vascular endothelial growth factor and not cyclooxygenase-2 promotes endothelial cell viability in the pancreatic tumour micro-environment. Pancreas 39(5):595–603
Van Cutsem E et al (2012) Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 30(28):3499–3506
Varricchi G et al (2017) Are mast cells MASTers in cancer? Front Immunol 8:424
von Marschall Z et al (2003) Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst 95(6):437–448
Wada J et al (2009) The contribution of vascular endothelial growth factor to the induction of regulatory T-cells in malignant effusions. Anticancer Res 29:881–888
Wu WZ, Sun HC, Shen YF, Chen J, Wang L, Tang ZY et al (2005) Interferon alpha 2a down-regulates VEGF expression through PI3 kinase and MAP kinase signalling pathways. J Cancer Res Clin Oncol 131(3):169–178
Wu L, Saxena S, Singh RK (2020) Neutrophils in the tumor microenvironment. In: Birbrair A (ed) Tumor microenvironment, Advances in experimental medicine and biology, vol 1224. Springer, Cham
Zhao Y, Li W (2019) Beta-adrenergic signaling on neuroendocrine differentiation, angiogenesis, and metastasis in prostate cancer progression. Asian J Androl 21(3):253–259
Zhao X et al (2014) Hypoxia-inducible factor-1 promotes pancreatic ductal adenocarcinoma invasion and metastasis by activating transcription of the actin-bundling protein fascin. Cancer Res 74(9):2455–2464
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 Springer Nature Switzerland AG
About this entry
Cite this entry
Murphy, J.F. (2022). Angiogenesis and the Tumor Microenvironment. In: Rezaei, N. (eds) Handbook of Cancer and Immunology. Springer, Cham. https://doi.org/10.1007/978-3-030-80962-1_87-1
Download citation
DOI: https://doi.org/10.1007/978-3-030-80962-1_87-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-80962-1
Online ISBN: 978-3-030-80962-1
eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences